| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies | Company's Home Page |
| BioMarin Pharmaceutical Inc. |
| 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 * (415) 884-6700 |
| Business Description | BioMarin Pharmaceutical Inc. is a leading developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. |
| Offering Information Company has | |||
| Trading As | BMRN (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 05/04/1999 |
| Domestic Shares Offered | 4,500,000 | Offer Date | 07/23/1999 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 4,500,000 | Offer Price | $13.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | - - |
| Gross Proceeds | $58,500,000 | Selling | - - |
| Expenses | - - | Reallowance | - - |
| Post-IPO Shares | 34,109,513 | Employees | 77 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| U.S. Bancorp Piper Jaffray | Lead Manager | (612) 342-6220 |
| Leerink Swann & Company | Co-manager | |
| Schroder Wertheim & Company, Incorporated | Co-manager | (212) 492-6900 |
| Vontobel Securities Ltd. | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1997 | 12/31/1998 | 03/31/1998 | 03/31/1999 | |||
| Revenues | - | - | - | 0.000 | 1.190 | 0.000 | 1.104 |
| Income from Oper. | - | - | - | -2.828 | -12.951 | -1.411 | -4.367 |
| Net Income | - | - | - | -2.762 | -12.313 | -1.319 | -4.394 |
| E.P.S | - | - | - | -0.340 | -0.550 | -0.060 | -0.170 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.06 | -1.37 | -4.09 | ||||
| Cash Flow - Inv. | -8.19 | -4.21 | -1.70 | ||||
| Cash Flow - Fin. | 19.60 | -0.04 | -0.04 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 03/31/1999 | Financial Ratios | ||||
| Total Assets | 26.78 | Current Assets | 5.53 | Current Ratio | 3.39 |
| Total Liab. | 1.73 | Current Liab. | 1.63 | Debt Ratio | 6.47% |
| Total Equity | 25.05 | Working Cap. | 3.90 | Debt to Equity Ratio | 0.07 |
| Cash | 3.57 | Return on Assets | - | ||
| Use Of Proceeds |
The company intends on using the net proceeds of this offering for the following purposes: To fund our share of costs associated with the development and commercialization of BM101; To fund research and development including clinical trials, regulatory processes and manufacturing for our product programs; For process development, scale-up and start-up of manufacturing activities; For research, development, clinical and commercial manufacturing facilities, including related equipment; General corporate purposes. A portion of the proceeds may also be used to acquire or invest in complementary businesses or products or to obtain rights to use complementary technologies. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |